Exelixis | EXEL - Sales Revenues

Exelixis reported $479.65M in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
Acadia Pharmaceuticals USD 231.04M 19.34M Dec/2023
Agios Pharmaceuticals USD 7.1M 296K Dec/2023
Amgen USD 8.2B 1.29B Dec/2023
AstraZeneca USD 12.02B 532M Dec/2023
Bayer EUR 11.86B 1.52B Dec/2023
BioMarin Pharmaceutical USD 649M 2.79M Mar/2024
Bristol-Myers Squibb USD 11.9B 423M Mar/2024
Cytokinetics USD 1.67M 1.29M Dec/2023
Eisai JPY 177.7B 1.09B Dec/2023
Eli Lilly USD 9.35B 145.2M Dec/2023
Exelixis USD 479.65M 7.73M Dec/2023
Genmab DKK 4.68B 66M Dec/2023
Glaxosmithkline GBP 8.05B 95M Dec/2023
Incyte USD 1.01B 94.32M Dec/2023
Ionis Pharmaceuticals USD 325M 180.79M Dec/2023
MacroGenics USD 10.72M 323K Dec/2023
Merck USD 15.8B 1.17B Mar/2024
Moderna USD 2.81B 980M Dec/2023
Neurocrine Biosciences USD 515.2M 16.4M Dec/2023
Novartis USD 11.83B 54M Mar/2024
Pfizer USD 14.25B 1.02B Dec/2023
Sanofi EUR 11.75B 1.26B Dec/2023
Takeda JPY 1.11T 68.1B Dec/2023
Ultragenyx Pharmaceutical USD 127.39M 29.34M Dec/2023
Xencor USD 44.69M 14.48M Dec/2023